• TOWA Pharmaceutical booked a JPY 2.36 billion non-operating derivatives valuation loss for the six months ended Sept. 30, 2026.
• The loss reflected a stronger yen versus March 2026 levels and a wider gap between Japanese and US long-term interest rates.
• Full-year guidance for March 2027 remains unchanged from May 14, 2026; it excludes derivatives valuation gains and losses amid exchange-rate uncertainty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOWA Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.